SUBSCRIBE: eNewsletter
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)
What's new: reliable outcome measures, overlap in treatment targets, and immune checkpoint inhibitors.
Various biologics that focus on the IL-17 pathway are currently being studied.
British investigators take a long-range view of tumor necrosis factor inhibitors in patients with psoriatic arthritis.
An expanded role for MRI and 2 recently approved treatment options.
Highlights of 5 topline news stories from the FDA, CDC, and American College of Rheumatology—with real-world implications for primary care practice.
New data highlight the role of the C5a-C5aR axis in the onset of inflammation.
Moderate to high disease activity may persist.
Here’s a brief look at medications for rheumatologic disorders that were newly approved in the last quarter of 2017.
The first oral JAK inhibitor approved for both moderate to severe RA and active PsA.
Psoriatic arthritis is the second approved indication for Taltz in the United States.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
